The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2020 | Immunotherapy for treating multiple myeloma
Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, discusses immunotherapeutic interventions to treat multiple myeloma. Dr Raje highlights allogeneic CAR T-cells that are currently in clinical trials. Belantamab mafodotin, an immunoconjugate targeting B-cell maturation antigen (BCMA), as used in the DREAMM trials (NCT04126200/NCT03525678), is now approved by the FDA and benefits patients for up to 3 months. Immunotherapies are off the shelf and easier than cell therapies. As both immunotherapies and cell therapies target the same antigen, which is BCMA, incorporating both therapies in the future could show benefit for multiple myeloma patients. Additionally, Dr Raje discusses Bispecific T-cell engager (BiTEs) antibodies, including teclistamab. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.
